相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。The role of patient-derived ovarian cancer organoids in the study of PARP inhibitors sensitivity and resistance: from genomic analysis to functional testing
Mengyu Tao et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2021)
Understanding and overcoming resistance to PARP inhibitors in cancer therapy
Mariana Paes Dias et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2021)
Classification of variants of uncertain significance in BRCA1 and BRCA2 using personal and family history of cancer from individuals in a large hereditary cancer multigene panel testing cohort
Hongyan Li et al.
GENETICS IN MEDICINE (2020)
EVOLVE: A Multicenter Open-Label Single-Arm Clinical and Translational Phase II Trial of Cediranib Plus Olaparib for Ovarian Cancer after PARP Inhibition Progression
Stephanie Lheureux et al.
CLINICAL CANCER RESEARCH (2020)
Distinct roles of BRCA2 in replication fork protection in response to hydroxyurea and DNA interstrand cross-links
Kimberly A. Rickman et al.
GENES & DEVELOPMENT (2020)
Developing Organoids from Ovarian Cancer as Experimental and Preclinical Models
Nina Maenhoudt et al.
STEM CELL REPORTS (2020)
PARP inhibitor resistance: the underlying mechanisms and clinical implications
He Li et al.
MOLECULAR CANCER (2020)
Combining PARP with ATR inhibition overcomes PARP inhibitor and platinum resistance in ovarian cancer models
Hyoung Kim et al.
NATURE COMMUNICATIONS (2020)
Patient-derived ovarian cancer organoids capture the genomic profiles of primary tumours applicable for drug sensitivity and resistance testing
Yoshiko Nanki et al.
SCIENTIFIC REPORTS (2020)
Patient-Derived Ovarian Cancer Organoids Mimic Clinical Response and Exhibit Heterogeneous Inter- and Intrapatient Drug Responses
Chris Jenske de Witte et al.
CELL REPORTS (2020)
PARP Inhibitors: Extending Benefit Beyond BRCA-Mutant Cancers
Patrick G. Pilie et al.
CLINICAL CANCER RESEARCH (2019)
Olaparib and α-specific PI3K inhibitor alpelisib for patients with epithelial ovarian cancer: a dose-escalation and dose-expansion phase 1b trial
Panagiotis A. Konstantinopoulos et al.
LANCET ONCOLOGY (2019)
An organoid platform for ovarian cancer captures intra- and interpatient heterogeneity
Oded Kopper et al.
NATURE MEDICINE (2019)
State-of-the-art strategies for targeting the DNA damage response in cancer
Patrick G. Pilie et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2019)
RAD51 foci as a functional biomarker of homologous recombination repair and PARP inhibitor resistance in germline BRCA-mutated breast cancer
C. Cruz et al.
ANNALS OF ONCOLOGY (2018)
Acetylation blocks DNA damage-induced chromatin ADP-ribosylation
Glen Liszczak et al.
NATURE CHEMICAL BIOLOGY (2018)
Prediction of DNA Repair Inhibitor Response in Short-Term Patient-Derived Ovarian Cancer Organoids
Sarah J. Hill et al.
CANCER DISCOVERY (2018)
Candidate biomarkers of PARP inhibitor sensitivity in ovarian cancer beyond the BRCA genes
Darren R. Hodgson et al.
BRITISH JOURNAL OF CANCER (2018)
Mutations in Homologous Recombination Genes and Outcomes in Ovarian Carcinoma Patients in GOG 218: An NRG Oncology/Gynecologic Oncology Group Study
Barbara M. Norquist et al.
CLINICAL CANCER RESEARCH (2018)
ATR inhibition disrupts rewired homologous recombination and fork protection pathways in PARP inhibitor-resistant BRCA-deficient cancer cells
Stephanie A. Yazinski et al.
GENES & DEVELOPMENT (2017)
Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial
Robert L. Coleman et al.
LANCET (2017)
EZH2 promotes degradation of stalled replication forks by recruiting MUS81 through histone H3 trimethylation
Beatrice Rondinelli et al.
NATURE CELL BIOLOGY (2017)
Disease Modeling in Stem Cell-Derived 3D Organoid Systems
Devanjali Dutta et al.
TRENDS IN MOLECULAR MEDICINE (2017)
Replication fork stability confers chemoresistance in BRCA-deficient cells
Arnab Ray Chaudhuri et al.
NATURE (2016)
The Fanconi anaemia pathway: newyplayers and new functions
Raphael Ceccaldi et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2016)
Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer
M. R. Mirza et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
CDK12 Inhibition Reverses De Novo and Acquired PARP Inhibitor Resistance in BRCA Wild-Type and Mutated Models of Triple-Negative Breast Cancer
Shawn F. Johnson et al.
CELL REPORTS (2016)
Effect of KRAS exon 2 mutations on antitumor activity of afatinib and gefitinib
Sebastian Gamba et al.
ANTI-CANCER DRUGS (2015)
PAX2 and PAX8 Reliably Distinguishes Ovarian Serous Tumors From Mucinous Tumors
Min Wang et al.
APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY (2015)
Germline and Somatic Mutations in Homologous Recombination Genes Predict Platinum Response and Survival in Ovarian, Fallopian Tube, and Peritoneal Carcinomas
Kathryn P. Pennington et al.
CLINICAL CANCER RESEARCH (2014)
Integrated analysis of germline and somatic variants in ovarian cancer
Krishna L. Kanchi et al.
NATURE COMMUNICATIONS (2014)
Secondary mutations in BRCA2 associated with clinical resistance to a PARP inhibitor
Louise J. Barber et al.
JOURNAL OF PATHOLOGY (2013)
Loss of 53BP1 Causes PARP Inhibitor Resistance in Brca1-Mutated Mouse Mammary Tumors
Janneke E. Jaspers et al.
CANCER DISCOVERY (2013)
Control-FREEC: a tool for assessing copy number and allelic content using next-generation sequencing data
Valentina Boeva et al.
BIOINFORMATICS (2012)
Patterns of genomic loss of heterozygosity predict homologous recombination repair defects in epithelial ovarian cancer
V. Abkevich et al.
BRITISH JOURNAL OF CANCER (2012)
Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors
Junko Murai et al.
CANCER RESEARCH (2012)
PI3K Inhibition Impairs BRCA1/2 Expression and Sensitizes BRCA-Proficient Triple-Negative Breast Cancer to PARP Inhibition
Yasir H. Ibrahim et al.
CANCER DISCOVERY (2012)
Definitions for Response and Progression in Ovarian Cancer Clinical Trials Incorporating RECIST 1.1 and CA 125 Agreed by the Gynecological Cancer Intergroup (GCIG)
Gordon John Sampson Rustin et al.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER (2011)
Secondary Somatic Mutations Restoring BRCA1/2 Predict Chemotherapy Resistance in Hereditary Ovarian Carcinomas
Barbara Norquist et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study
Karen A. Gelmon et al.
LANCET ONCOLOGY (2011)
The Genome Analysis Toolkit: A MapReduce framework for analyzing next-generation DNA sequencing data
Aaron McKenna et al.
GENOME RESEARCH (2010)
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial
M. William Audeh et al.
LANCET (2010)
The Sequence Alignment/Map format and SAMtools
Heng Li et al.
BIOINFORMATICS (2009)
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
E. A. Eisenhauer et al.
EUROPEAN JOURNAL OF CANCER (2009)
Inhibition of Poly(ADP-Ribose) Polymerase in Tumors from BRCA Mutation Carriers.
Peter C. Fong et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Listening to silence and understanding nonsense: Exonic mutations that affect splicing
L Cartegni et al.
NATURE REVIEWS GENETICS (2002)
分享论文
